Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children

• Published in: Vaccine 2004-11, Vol.23 (2), p.127-131
• Main Authors: Wood, C., Baeyer, C.L. von, Bourrillon, A., Dejos-Conant, V., Clyti, N., Abitbol, V.
• Format: Article
• Language: English
• Subjects: Applied microbiology; Autism; Biological and medical sciences; Child; Child, Preschool; Female; FPS-R; Fundamental and applied biological sciences. Psychology; Humans; Immunization; Injections, Subcutaneous; Male; Measles-Mumps-Rubella Vaccine - administration & dosage; Measles-Mumps-Rubella Vaccine - adverse effects; Microbiology; MMR; Multicenter Studies as Topic; Mumps; Pain; Pain - etiology; Pain Measurement - methods; Psychology, Child; Safety; Vaccination - adverse effects; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2004.08.029

The aim of this study was to compare self-reported immediate post-vaccination pain and safety of Priorix ® versus RORVax ® in 4- to 6-year-old children receiving their second dose of MMR vaccine, using the Faces Pain Scale-Revised (FPS-R), a validated self-report pain scale recommended by the French National Accreditation Agency and Health Evaluation. A total of 620 children from 28 French pediatricians completed all study procedures. Immediate post-vaccination pain was reported by 17.8% of the subjects in Priorix ® group ( N = 309) and by 44.7% of the subjects in RORVax ® group ( N = 311) [OR = 3.7; P < 0.001]. Parents’ pain scores correlated significantly with children's scores. The reduction of immediate pain incidence in Priorix ® group persisted over the 4 post-vaccination days. This study, using a validated self-assessment pain scale, confirmed previous data showing a significantly lower incidence of immediate post-vaccination pain with Priorix ® as compared to RORVax ®.